↓ Skip to main content

EpCAM as multi-tumour target for near-infrared fluorescence guided surgery

Overview of attention for article published in BMC Cancer, November 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
36 Dimensions

Readers on

mendeley
64 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
EpCAM as multi-tumour target for near-infrared fluorescence guided surgery
Published in
BMC Cancer, November 2016
DOI 10.1186/s12885-016-2932-7
Pubmed ID
Authors

P. B. A. A. van Driel, M. C. Boonstra, H. A. J. M. Prevoo, M. van de Giessen, T. J. A. Snoeks, Q. R. J. G. Tummers, S. Keereweer, R. A. Cordfunke, A. Fish, J. D. H. van Eendenburg, B. P. F. Lelieveldt, J. Dijkstra, C. J. H. van de Velde, P. J. K. Kuppen, A. L. Vahrmeijer, C. W. G. M. Löwik, C. F. M. Sier

Abstract

Evaluation of resection margins during cancer surgery can be challenging, often resulting in incomplete tumour removal. Fluorescence-guided surgery (FGS) aims to aid the surgeon to visualize tumours and resection margins during surgery. FGS relies on a clinically applicable imaging system in combination with a specific tumour-targeting contrast agent. In this study EpCAM (epithelial cell adhesion molecule) is evaluated as target for FGS in combination with the novel Artemis imaging system. The NIR fluorophore IRDye800CW was conjugated to the well-established EpCAM specific monoclonal antibody 323/A3 and an isotype IgG1 as control. The anti-EpCAM/800CW conjugate was stable in serum and showed preserved binding capacity as evaluated on EpCAM positive and negative cell lines, using flow cytometry and cell-based plate assays. Four clinically relevant orthotopic tumour models, i.e. colorectal cancer, breast cancer, head and neck cancer, and peritonitis carcinomatosa, were used to evaluate the performance of the anti-EpCAM agent with the clinically validated Artemis imaging system. The Pearl Impulse small animal imaging system was used as reference. The specificity of the NIRF signal was confirmed using bioluminescence imaging and green-fluorescent protein. All tumour types could clearly be delineated and resected 72 h after injection of the imaging agent. Using NIRF imaging millimetre sized tumour nodules were detected that were invisible for the naked eye. Fluorescence microscopy demonstrated the distribution and tumour specificity of the anti-EpCAM agent. This study shows the potential of an EpCAM specific NIR-fluorescent agent in combination with a clinically validated intraoperative imaging system to visualize various tumours during surgery.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 2%
Unknown 63 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 19%
Student > Ph. D. Student 9 14%
Student > Master 9 14%
Other 6 9%
Student > Bachelor 5 8%
Other 8 13%
Unknown 15 23%
Readers by discipline Count As %
Medicine and Dentistry 18 28%
Biochemistry, Genetics and Molecular Biology 6 9%
Pharmacology, Toxicology and Pharmaceutical Science 5 8%
Agricultural and Biological Sciences 3 5%
Immunology and Microbiology 3 5%
Other 10 16%
Unknown 19 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2023.
All research outputs
#7,990,681
of 24,727,020 outputs
Outputs from BMC Cancer
#2,154
of 8,766 outputs
Outputs of similar age
#111,254
of 313,436 outputs
Outputs of similar age from BMC Cancer
#29
of 103 outputs
Altmetric has tracked 24,727,020 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 8,766 research outputs from this source. They receive a mean Attention Score of 4.6. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 313,436 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 103 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.